What is the incidence of atrophic lesions in patients with Stargardt disease?
In a multicenter cohort study of 217 patients, the median time to develop a definitely decreased autofluorescence lesion was 4.9 years among the eyes with questionably decreased autofluorescence but no definitely decreased autofluorescence at the baseline visit. Among eyes without questionably decreased autofluorescence, the median time to develop such a lesion was 6.3 years.
These results suggest that the incidence of atrophic lesions may serve as an outcome measure for trials of sufficient duration in Stargardt disease.
Outcome measures that are sensitive to disease progression are needed as clinical end points for future treatment trials in Stargardt disease.
To examine the incidence of atrophic lesions of the retinal pigment epithelium in patients with Stargardt disease as determined by fundus autofluorescence imaging.
Design, Setting, and Participants
In this retrospective multicenter cohort study, 217 patients 6 years and older at baseline at tertiary referral centers in Europe, the United States, and the United Kingdom who were harboring disease-causing variants in the adenosine triphosphate (ATP)–binding cassette subfamily A member 4 (ABCA4) gene and who met the following criteria were enrolled: (1) at least 1 well-demarcated area of atrophy with a minimum diameter of 300 µm, with the total area of all atrophic lesions being less than or equal to 12 mm2 in at least 1 eye at the most recent visit, and (2) fundus autofluorescence images for at least 2 visits with a minimum of 6 months between at least 2 visits. Data were collected between August 22, 2013, and December 12, 2014. Data analysis was performed from March 15, 2015, through January 31, 2017.
Images were evaluated by staff at a central reading center. Areas of definitely decreased autofluorescence (DDAF) and questionably decreased autofluorescence (QDAF) were outlined and quantified. Lesion-free survival rates were estimated using Kaplan-Meier survival curves.
Main Outcomes and Measures
Incidence of atrophic lesions as determined by fundus autofluorescence.
The 217 patients (mean [SD] age, 21.8 [13.3] years; 127 female [57.5%]; 148 white [68.2%]) contributed 390 eyes for which the mean (SD) follow-up time was 3.9 (1.6) years (range, 0.7-12.1 years). Among eyes without DDAF at first visit, the median time to develop a DDAF lesion was 4.9 years (95% CI, 4.3-5.6 years). Among eyes without QDAF, the median time to develop a QDAF lesion was 6.3 years (95% CI, 5.6-9.7 years). Eyes with a lesion of DDAF at the first visit were less likely to develop a QDAF lesion compared with eyes without a lesion of DDAF (hazard ratio, 0.19; 95% CI, 0.05-0.70; P = .01).
Conclusions and Relevance
An estimated 50% of the eyes without DDAF at first visit will develop the lesion in less than 5 years, suggesting that incidence of DDAF could serve as an outcome measure for treatment trials.
The most common juvenile macular degeneration is Stargardt macular dystrophy (Stargardt disease 1 [STGD1]; OMIM: 248200), with a prevalence of 10 to 12.5 per 100 000 persons; it is inherited as an autosomal-recessive trait attributable to disease-causing mutations in the adenosine triophosphate (ATP)–binding cassette subfamily A member 4 (ABCA4) (OMIM 601691) gene.1,2Quiz Ref ID Although there is currently no treatment approved by the US Food and Drug Administration, several treatment approaches, including gene augmentation, stem cell therapy, and pharmacotherapy, are in early clinical trials.1,3,4 Measurement of enlargement of geographic atrophy is being used as a primary outcome measure in current trials.5 Use of fundus autofluorescence (FAF), as opposed to the traditional color fundus photography, provides the advantages of better distinction and delineation between dead and nonfunctioning retinal pigment epithelium and living but depigmented retinal pigment epithelium.6 The concept that atrophic areas in geographic atrophy have a markedly reduced autofluorescent signal, thereby indicating and reflecting loss of retinal pigment epithelium cells, is widely accepted and also considered as a potential surrogate end point by the US Food and Drug Administration.3,5 The incidence of new lesions as defined using FAF in eyes at risk for developing these lesions has not been well studied.
The Progression of Atrophy Secondary to Stargardt Disease (ProgStar) retrospective study (NCT01977846) is an ideal study to address the incidence of new FAF lesions because the entry criteria allowed eyes with no lesion at the first baseline visit and the observational period is longer than in the prospective study. The purpose of this article is to report the incidence of atrophic lesions in the retrospective ProgStar study as determined by FAF.
The study was conducted according to the International Conference on Harmonisation Good Clinical Practice Guidelines, the applicable regulatory requirements, the current Declaration of Helsinki,7 and the Health Insurance Portability and Accountability Act. Ethics committee approval was granted by the Western Institutional Review Board, the local institutional review boards (Cleveland Clinic Institutional Review Board; the University of Texas Southwestern Institutional Review Board; the Greater Baltimore Medical Center Institutional Review Board; the Johns Hopkins University, School of Medicine, Office of Human Subjects Research Institutional Review Boards; University of Pennsylvania, Office of Regulatory Affairs, Institutional Review Board; University of Utah Institutional Review Board; National Health Service Health Research Authority, London–Queen Square Research Ethics Committee; French National Commission of Data Processing and Liberties; Ethics Committee of the Medical Faculty of the Eberhard-Karls University and of the University Hospitals, Tübingen), and the Human Research Protection Office of the US Army Medical Research and Materiel Command before enrollment of the first patient. However, all except one local institutional review board (French National Commission of Data Processing and Liberties) exempted the centers from an informed consent process; at this institution, written informed consent was obtained from participants before enrollment.
Quiz Ref IDThe design, inclusion and exclusion criteria, and the participants in the retrospective ProgStar study have been described in detail previously.3 Briefly summarized for the purpose of this article, the key inclusion criteria required the presence of the following: (1) at least 2 pathogenic mutations in the ABCA4 gene (presence of 1 mutation was accepted in case the clinical phenotype was typical for Stargardt disease; ie, with flecks on the level of the retinal pigment epithelium); (2) the same examination modality was available for at least 2 visits for FAF obtained with an angiograph instrument (eg, Heidelberg Retina Angiograph 2 [HRA2], Heidelberg Engineering), spectral domain optical coherence tomograph (SD-OCT) obtained with an expandable diagnostic imaging platform (Spectralis, Heidelberg Engineering), and/or microperimetry at least 6 months apart; (3) 1 well-defined atrophic lesion in at least 1 eye at the most recent visit that measured at least 300 µm in diameter as determined by the site’s principal investigator; however, the area of all lesions together must have been less than or equal to 12 mm2 (corresponding to no more than 5 disc areas); (4) sufficient quality of images; and (5) minimal age of 6 years at the most recent visit. Participants in the retrospective study could have had 2, 3, or 4 visits. The observational period between 2 single visits was between 6 and 60 months.
Patient medical records were reviewed by the participating clinical sites to gather data such as age at enrollment, sex, race, visual acuity, findings derived from ophthalmologic examination, and vitamin A supplementation and sent to the data coordinating center (Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland). FAF image obtainment with a Heidelberg Engineering device was required; infrared reflectance images obtained with such a device (eg, HRA2 or Heidelberg Spectralis HRA+OCT [excitation light, 815 nm]) were also accepted.
Deidentified FAF images of eligible patients were sent by the sites to the central reading center (Doheny Imaging Reading Center, David Geffen School of Medicine at UCLA [University of California, Los Angeles]), where they were evaluated for focus and clarity. The FAF imaging grading protocols included qualitative and quantitative factors.
Qualitative Grading Factors
An even background FAF is characterized by a smooth distribution of FAF with a decrease at the fovea based on the presence of macular pigment,6 in contrast to an irregular background FAF with the presence of mottled, speckled, or reticular pattern of FAF. Irregular background FAF was graded independent of discrete areas of abnormal FAF.
Qualitative grading factors included absence or presence of flecks in and outside the arcades. Uniformity of the background FAF was graded based on 2 categories proposed by Fujinami et al8: a homogeneous background signal was defined as an even distribution of background autofluorescence and a heterogeneous background signal was characterized by widespread small foci of increased or reduced autofluorescence.
Quantitative Grading Factors
The grading scheme for quantitative assessment of different types of decreased areas of autofluorescence was published previously.9,10 Qualitative measures of darkness and lesion border determined distinct lesion types (Figure 1): definitely decreased autofluorescence (DDAF) and questionably decreased autofluorescence (QDAF). Reference points for gray levels were the background and the optic disc and nerve head, respectively; the periphery of an image often revealed a normal retina with undisturbed areas and a homogeneous background. The optic nerve disc and head were set as the reference point to determine the 100% degree of blackness. For all types, the pattern of decreased areas of autofluorescence had to appear as different (darker) from the background gray level and the lesion diameter had to be 125 μm or larger (approximately equal to the diameter of a vein originating from the optic disc) according to grading protocols. The distinct types of decreased areas of autofluorescence had differences in the black level: if an area of interest was more than 90% black (where the optic disc was defined as being 100% black), this was defined as DDAF, whereas an area of interest with black levels ranging from 50% to 90% was defined as QDAF.
The size of the areas was semiautomatically evaluated using the RegionFinder module of the Heidelberg Eye Explorer (Heidelberg Engineering) review software. The previously described conventions were used11: application of shadow correction when the FAF images were unevenly or inadequately illuminated; each noncontiguous area of decreased autofluorescence has been quantified separately if needed; algorithm growth power was adjusted and refined manually until the region fully captured the area of decreased FAF; and manual line, circle, or free-hand constraints were used as needed to distinguish lesion boundaries and exclude vascular structures. The sum of all areas of respective decreased areas of autofluorescence (within each subtype) was calculated in cases of presence of multifocal lesions.
The FAF images were evaluated independently and objectively. Each image type was initially assessed with masking from information from other image types or visits. The reading center allowed graders to eventually reference all available image types from that visit date if desired and available; in ambiguous cases, graders were allowed to reference the grading decisions from the patient’s previous visits to guide grading of the images from the current visit. At least 1 of the graders was a senior-level grader. All cases of discordant initial answers underwent adjudication, and the final answer was determined by a reading center investigator.
In 8 visits of 7 patients (16 eye visits), the method using the RegionFinder tool could not be applied because of image size constraints. In these patients, grading was performed using a planimetric grading software program (GRADOR), custom built for use by the reading center, because very good concordance with the Heidelberg RegionFinder was previously reported.9 Only grades determined by the reading center were included in the analyses.
The incidence of an outcome was defined as the first visit in which the lesion appeared in eyes that did not have the lesion at their baseline visit (but eyes could have other lesions). Outcomes were the appearance of flecks, heterogeneous background, QDAF, and DDAF. The median time to event and cumulative incidence to 3 and 5 years were calculated using Kaplan-Meier product-limit survival estimates. To adjust for baseline characteristics that possibly influenced incidence, multivariate models were constructed for outcomes using Cox proportional hazard regression models; robust sandwich covariance estimates were used to correct SEs to account for correlation between eyes of the same patient. Statistical analyses were conducted using SAS statistical software, version 9.3 (SAS Institute Inc), and R project for statistical computing, version 2.15.1 (Institute for Statistics and Mathematics).
Characteristics associated with the presence of DDAF and QDAF lesions were examined cross-sectionally at baseline. Logistic regression models were created to test for significant associations. The generalized estimated equation approach was used to account for the correlation between eyes of the same patient. Age adjusted odds ratios are presented. We present 2-sided age-adjusted P values. The CIs and P values are based on the empirical SE estimates from the generalized estimating equation model.
A total of 251 patients with pathogenic mutations in the ABCA4 gene were enrolled at 9 clinical centers in Europe, the United Kingdom, and the United States between August 2, 2013, and December 12, 2014; these patients were seen for visits at the participating sites between August 14, 2001, and December 9, 2014. Data analysis was performed from March 15, 2015, through January 31, 2017. The FAF images for at least 2 visits were available in 217 patients (mean [SD] age, 21.8 [13.3] years; 127 female [57.5%]; 148 white [68.2%]), of whom 173 patients (79.7%) were enrolled with both eyes and 44 patients (20.3%) with 1 eye, for a total of 390 study eyes. Table 1 summarizes the patient characteristics at the first visit. The mean (SD) follow-up time was 3.9 (1.6) years (range, 0.7-12.1 years; median follow-up, 3.6 years; interquartile range, 2.7-5.0 years).
The presence and absence of the qualitative grading parameters flecks and background heterogeneity for eyes with DDAF and/or QDAF lesions at the first visit are summarized in Table 2. Nearly all eyes with an area of DDAF also had flecks. The presence of DDAF lesions was negatively associated with the presence of QDAF lesions. The QDAF lesions were present in 85% of the eyes without DDAF compared with 39% of the eyes with DDAF (age-adjusted odds ratio, 0.10; 95% CI, 0.05-0.3; P<.001) (Table 3). Only 10 eyes at baseline had neither DDAF nor QDAF.
Incidence of Qualitative Factors
At the first visit, 57 (14.6%) of the 390 eyes did not have any flecks. The estimated cumulative incidence to 3.0 years was 37%, and the median time to develop flecks was 4.9 years (95% CI, 2.9-6.1 years). A total of 263 eyes (67.4%) had a homogeneous background at the first visit, the estimated 3-year cumulative incidence of a heterogeneous background in eyes without the feature at first visit was 6.4%, and the median time to develop a heterogeneous background was estimated to be 8.0 years (95% CI, 8.0-12.0 years) (Table 3). All eyes with a heterogeneous background at the first visit also had a heterogeneous background at the most recent visit.
Incidence of DDAF Lesions
At the first visit, 206 eyes (52.8% of all eyes) did not have any area of DDAF, although all but 10 eyes had QDAF. Quiz Ref IDThe median time to develop DDAF lesions was 4.9 years (95% CI, 4.3-5.6 years), and by 3.0 years, 24% had developed such a lesion (Figure 2). There was no increased probability of developing a lesion of DDAF when there was baseline QDAF at the first visit (Figure 2). There was also no difference in the probability of developing such a lesion depending on the presence or absence of flecks (hazard ratio [HR], 1.14; 95% CI, 0.72-1.83; P = .57); however, compared with eyes with homogeneous background, eyes with heterogeneous background at the first visit were more likely to develop DDAF lesions (median time, 3.6 years for eyes with a heterogeneous background and 4.9 years for eyes with a homogeneous background; HR, 1.90; 95% CI, 1.17-3.06; P = .009). However, after adjusting for age at onset, the HR decreased to 1.54 (95% CI, 0.84-2.83; P = .16).
Incidence of QDAF Lesions
The number of eyes at risk of developing QDAF lesions was 69, with all but 10 eyes having DDAF. Median time to develop QDAF lesions was 6.3 years (95% CI, 5.6-9.7) (Figure 2). There was no difference in the probability of developing QDAF lesions between eyes with and without flecks at the first visit (HR, 0.72; 95% CI, 0.11-4.69; P = .70) or between the eyes with a heterogeneous or homogeneous background (HR, 0.39; 95% CI, 0.07-2.45; P = .39). However, eyes with a DDAF lesion at the first visit were less likely to develop a QDAF lesion compared with eyes without a DDAF lesion at first visit (HR, 0.19; 95% CI, 0.05-0.70; P = .01).
The findings in this report add valuable information about the natural course of Stargardt disease. A previous study12 correlating DDAF and QDAF as determined by SD-OCT found a difference in the layers between the external limiting membrane and the inner boundary of the choroid, indicating a relative reduction in thickness for these layers in DDAF, and a difference for all the layers, indicating a relative decrease in preserved areas for all the layers in DDAF. This finding suggests that QDAF may be considered as a transition state between healthy retina and later stages of Stargardt disease, thus proposing Stargardt disease progression.
Quiz Ref IDBecause the median time for the development of DDAF lesions was 4.93 years in our cohort, this may be a suitable outcome measure in studies with longer follow-up. Similarly, the incidence of QDAF lesions provided further insight into the progression of Stargardt disease. We observed 2 major groups of patients with DDAF lesions at baseline: one with solely DDAF lesions and one with DDAF and (nearly always surrounding) QDAF lesions. The lower likelihood for the development of QDAF lesions in eyes with the presence of DDAF lesions at the first visit vs eyes without such lesions may implicate that DDAF lesions expand and increase in size over time without the development of new QDAF lesions.
Outcome measures for forthcoming treatment trials on Stargardt disease are needed. At present, FAF imaging is widely applied in inherited retinal dystrophy clinics and has been used as an outcome measure in clinical trials for age-related macular degeneration,13 and areas of decreased autofluorescence have a correlation with morphofunctional outcomes in eyes affected by Stargardt disease.14 Previous results from single-center observational studies8,15,16 in Stargardt disease have reported the growth of atrophic lesions, corresponding to lesions defined here as DDAF. The growth rate of atrophic lesions is also the primary outcome in the multicenter ProgStar studies; however, these studies were designed in an exploratory way to get a deeper understanding of the natural course of Stargardt disease and investigate additional potential outcome measures for this phenotypically heterogeneous disease. Thus, additional evaluation of QDAF lesions and qualitative grading factors were included in the grading protocols. The development of new lesions was included in the study protocol of the retrospective study by requiring the presence of a well-defined lesion of atrophy at only the most recent visit (in contrast to the prospective study in which the presence of an atrophic lesion at baseline was an inclusion criterion). As described previously,3 the variability of clinical phenotypes was challenging for the ProgStar studies, but some eyes did not fulfill this requirement when graded by reading center criteria because it is well known that Stargardt disease may manifest with different patterns of reduced autofluorescence and clear, discernible atrophic lesions still may have poorly demarcated borders. The design may have led to some skews. First, the lesion size at the most recent visit was restricted to have a minimum width of 300 µm and a maximum area of 5 standard disc areas (corresponding to 12 mm2) in at least one eye, and thus larger lesions were eliminated. Second, the requirement that a lesion needed to be present at the most recent visit may bias the incidence estimates toward higher values because eyes with slower incidence rates were likely to have been excluded. Third, the number of evaluated visits could be as low as 2 visits; furthermore, the observational period was variable between 2 and 15 years.3
The retrospective study design also has inherent limitations. In addition to the requirement for a minimum lesion size at the most recent visit, we required at least 2 visits with FAF gradable images at least 24 months apart, although there could be interim FAF images as well. Of the original enrollment in the retrospective study of 251 patients, 34 did not have 2 FAF images and were not included. In addition, there may be patients at the sites who were not followed up and would not have been enrolled in our study. To the extent that such patients had incidence rates different from the ones that we determined, our estimates could be greater or smaller. Another limitation based on the retrospective design can be issues with image quality. Some images may have poor illumination or exposure, which affects the subjective darkness-level assessment (and the software’s attempt at a shadow correction).
To our knowledge, the incidence of atrophic lesions in Stargardt disease has not been reported previously, which may be explained by the wide range of phenotypical appearances and disease severity from early or childhood-onset17,18 to late-onset19 disease in Stargardt disease. We also acknowledge that the data provided in this report represent an incidence based on a cohort recruited according to the aforementioned inclusion criteria and may therefore not be applicable in routine clinical practice. There are other risk factors, such as smoking, that may promote a faster progression of eye diseases, including macular degeneration20; however, recording of smoking history was insufficient in this retrospective arm of the ProgStar studies and was only performed in the prospective study.3 Similarly, we faced problems when extracting patient medical records on vitamin A supplementation because this was not consistently registered in patient medical records in the past and therefore was only available for a few patients, especially those participating in the prospective study.
An estimated 50% of the eyes without DDAF at first visit will develop the lesion in less than 5 years, suggesting that incidence of DDAF could serve as an outcome measure for treatment trials. The prospective ProgStar study will evaluate further the incidence, particularly of DDAF lesions, during a 2-year period and elucidate the structural (as determined by SD-OCT)21 and functional (as determined by microperimetry)22 consequences.
Corresponding Author: Hendrik P. N. Scholl, MD, MA, Department of Ophthalmology, University of Basel, Universitätsspital Basel, Mittlere Strasse 91, CH-4031 Basel, Switzerland (firstname.lastname@example.org).
Accepted for Publication: March 21, 2017.
Published Online: May 25, 2017. doi:10.1001/jamaophthalmol.2017.1121
Author Contributions: Dr Scholl had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Strauss, Munoz, Michaelides, Birch, Scholl.
Acquisition, analysis, or interpretation of data: Strauss, Ho, Jha, Michaelides, Mohand-Said, Cideciyan, Hariri, Nittala, Sadda, Scholl.
Drafting of the manuscript: Strauss, Munoz, Michaelides, Hariri, Scholl.
Critical revision of the manuscript for important intellectual content: Strauss, Ho, Jha, Michaelides, Mohand-Said, Cideciyan, Birch, Nittala, Sadda, Scholl.
Statistical analysis: Munoz.
Obtained funding: Strauss, Michaelides, Cideciyan, Scholl.
Administrative, technical, or material support: Strauss, Ho, Jha, Michaelides, Mohand-Said, Cideciyan, Birch, Hariri, Scholl.
Study supervision: Jha, Cideciyan, Sadda, Scholl.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Birch reported working as a consultant for AGTC, Alachua, Florida; Acucela Inc, Seattle, Washington; Shire Pharmaceuticals, Lexington, Massachusetts; Ionis/GSK, Carlsbad, California; QLT, Vancouver, British Columbia, Canada; and Thrombogenics, Iselin, New Jersey. Dr Sadda reported receiving financial support from Optos, Marlborough, Massachusetts; Carl Zeiss Meditec, Jena, Germany; Nidek, Padova, Italy; Topcon Medical Systems, Oakland, New Jersey; Scientific Technical Advisory Committee at Alcon Research Institute, Fort Worth, Texas; and Research to Prevent Blindness Inc, New York, New York. Dr Scholl reported receiving support from the Foundation Fighting Blindness Clinical Research Institute and a grant to the Foundation Fighting Blindness Clinical Research Institute by the US Department of Defense, US Army Medical Research and Materiel Command, Telemedicine and Advanced Technology Research Center, Fort Meade, Maryland; and the Shulsky Foundation, New York, NY; working as a paid consultant for Astellas Institute for Regenerative Medicine, Boehringer Ingelheim Pharma GmbH & Co KG, Daiichi Sankyo Inc, Gerson Lehrman Group, Guidepoint, and Shire; serving as a member of the scientific advisory boards of Gensight Biologics, Vision Medicines Inc, and Intellia Therapeutics Inc; serving as a member of the data monitoring and safety boards or committees of Genentech Inc/F. Hoffmann-La Roche Ltd, Genzyme Corp/Sanofi, and ReNeuron Group Plc/Ora Inc; and previously serving as a member of the Ophthalmic Devices Panel of the Medical Devices Advisory Committee, US Food and Drug Administration, Silver Spring, Maryland. These arrangements have been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. Johns Hopkins University and Bayer Pharma AG have an active research collaboration and option agreement. These arrangements have also been reviewed and approved by the University of Basel in accordance with its conflict of interest policies. Dr Scholl reported serving as a principal investigator of grants at the University of Basel sponsored by the following entity: Acucela Inc, NightstaRx Ltd, and QLT Inc. Grants at the University of Basel are negotiated and administered by the institution, which receives them on its proper accounts. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor but may receive salary or other support from the institution to support their effort on the project(s). Dr Strauss reported receiving support from the Austrian Science Fund, Vienna, Austria, and Foundation Fighting Blindness Clinical Research Institute. Dr Cideciyan reported receiving partial support from the National Institutes of Health, Bethesda, Maryland. Dr Michaelides reported receiving support from a Foundation Fighting Blindess Career Development Award and the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital National Health Service Foundation Trust and University College London Institute of Ophthalmology, London, England. No other disclosures were reported.
Funding/Support: The ProgStar studies are supported by the Foundation Fighting Blindness Clinical Research Institute and grants W81-XWH-07-1-0720 and W81XWH-09-2-0189 to the Foundation Fighting Blindness Clinical Research Institute by the US Department of Defense, US Army Medical Research and Materiel Command, Telemedicine and Advanced Technology Research Center, Fort Meade, Maryland. Dr Scholl is supported by the Shulsky Foundation, New York, NY; Ocular Albinism Research Fund (Clark Enterprises Inc); an unrestricted grant to the Wilmer Eye Institute from Research to Prevent Blindness; and grant 1U54HG006542-01 from the Baylor-Johns Hopkins Center for Mendelian Genetics (National Human Genome Research Institute). Dr Strauss is supported by grant J 3383-B23 from the Austrian Science Fund. Dr Scholl is the Dr Frieda Derdeyn Bambas Professor of Ophthalmology.
Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.
Group Members: The ProgStar Study Group members are as follows: Chair’s Office: Hendrik P.N. Scholl, MD, Rupert W. Strauss, MD, Yulia Wolfson, MD, Millena Bittencourt, MD, Syed Mahmood Shah, MD, Mohamed Ahmed, MD, Etienne Schönbach, MD, Kaoru Fujinami, MD, PhD; Cole Eye Institute, Cleveland, Ohio: Elias Traboulsi, MD, Justis Ehlers, MD, Meghan Marino, MS, Susan Crowe, BS, Rachael Briggs, COA, Angela Borer, BS, Anne Pinter, CRA, Tami Fecko, Nikki Burgnoni, MS; Greater Baltimore Medical Center, Towson, Maryland: Janet S. Sunness, MD, Carol Applegate, MLA, COT, Leslie Russell, MAc; Moorfields Eye Hospital, London, England: Michel Michaelides, MD, Simona Degli Esposti, MD, Anthony Moore, Andrew Webster, MD, Sophie Connor, BSc, Jade Barnfield, BA, Zaid Salchi, MD, Clara Alfageme, MD, Victoria McCudden, Maria Pefkianaki, MD, Jonathan Aboshiha, MA, MB, Gerald Liew, Graham Holder, PhD, Anthony Robson, PhD, Alexa King, BA, Daniela Ivanova, Cajas Narvaez, MSc, Katy Barnard, BS, Catherine Grigg, BSc, Hannah Dunbar, PhD, Yetunde Obadeyi, Karine Girard-Claudon, MST, Hilary Swann, BSc, Avani Rughani, BSc, Charles Amoah, NVQ, Dominic Carrington, Kanom Bibi, BSc, Emerson Ting Co, DMD, Mohamed Nafaz Illiyas, Hamida Begum, BSc, Andrew Carter, BSc, Anne Georgiou, PhD, Selma Lewism BSc, Saddaf Shaheen, PGDip, BSc, Harpreet Shinmar, MSc, Linda Burton, BSc; Moran Eye Center, Salt Lake City, Utah: Paul Bernstein, MD, PhD, Kimberley Wegner, BS, Briana Lauren Sawyer, MS, Bonnie Carlstrom, COA, Kellian Farnsworth, COA, Cyrie Fry, AS, CRA, OCT-C, Melissa Chandler, BS, CRC, OCT-a, Glen Jenkins, BS, COA, CRC, OCT-a, Donnel Creel, PhD; Retina Foundation of the Southwest, Dallas, Texas: David Birch, PhD, Yi-Zhong Wang, PhD, Luis Rodriguez, BS, Kirsten Locke, BS, Martin Klein, MS, Paulina Mejia, BS; Scheie Eye Institute, Philadelphia, Pennsylvania; Artur V. Cideciyan, PhD, Samuel G. Jacobson, MD, PhD, Sharon B. Schwartz, MS, CGC, Rodrigo Matsui, MD, Michaela Gruzensky, MD, Jason Charng, OD, PhD, Alejandro J. Roman, MS; University of Tübingen, Tübingen, Germany: Eberhart Zrenner, PhD, Fadi Nasser, MD, Gesa Astrid Hahn, MD, Barbara Wilhelm, MD, Tobias Peters, MD, Benjamin Beier, BSc, Tilman Koenig, Susanne Kramer, Dipl Biol; The Vision Institute, Paris, France: José-Alain Sahel, MD, Saddek Mohand-Said, MD, PhD, Isabelle Audo, MD, PhD, Caroline Laurent-Coriat, MD, Ieva Sliesoraityte, MD, PhD, Christina Zeitz, PhD, Fiona Boyard, BS, Minh Ha Tran, BS, Mathias Chapon, COT, Céline Chaumette, COT, Juliette Amaudruz, COT, Victoria Ganem, COT, Serge Sancho, COT, Aurore Girmens, COT; The Wilmer Eye Institute, Baltimore, Maryland:Hendrik P. N. Scholl, MD, Rupert W. Strauss, MD, Yulia Wolfson, MD, Syed Mahmood Shah, MD, Mohamed Ahmed, MD, Etienne Schönbach, MD, Robert Wojciechowski, PhD, Shazia Khan, MD, David G. Emmert, BA, Dennis Cain, CRA, Mark Herring, CRA, Jennifer Bassinger, COA, Lisa Liberto, COA; Dana Center Data Coordinating Center; Sheila West, PhD, Ann-Margret Ervin, PhD, Beatriz Munoz, MS, Xiangrong Kong, PhD, Kurt Dreger, BS, Jennifer Jones, BA; Doheny Image Reading Center: Srinivas Sadda, MD, Michael S. Ip, MD, Anamika Jha, MBS, Alex Ho, BS, Brendan Kramer, BA, Ngoc Lam, BA, Rita Tawdros, BS, Yong Dong Zhou, MD, PhD, Johana Carmona, HS, Akihito Uji, MD, PhD, Amirhossein Hariri, MD, Amy Lock, BS, Anthony Elshafei, BS, Anushika Ganegoda, BS, Christine Petrossian, BS, Dennis Jenkins, MPH, Edward Strnad, BS, Elmira Baghdasaryan, MD, Eric Ito, OD, Feliz Samson, BS, Gloria Blanquel, BS, Handan Akil, MD, FEBOpht, Jhanisus Melendez, MS, Jianqin Lei, MD, Jianyan Huang, MD, PhD, Jonathan Chau, BS, Khalil G. Falavarjani, MD, Kristina Espino, BS, Manfred Li, BS, Maria Mendoza, BS, Muneeswar Gupta Nittala, MPhil Opt, Netali Roded, BS, Nizar Saleh, MD, Ping Huang, MD, PhD, Sean Pitetta, BS, Siva Balasubramanian, MD, PhD, Sophie Leahy, BA, Sowmya J. Srinivas, MBBS, Swetha B. Velaga, B Opt, Teresa Margaryan, BA, Tudor Tepelus, PhD, Tyler Brown, BS, Wenying Fan, MD, Yamileth Murillo, BA, Yue Shi, MD, PhD, Katherine Aguilar, BS, Cynthia Chan, BS, Lisa Santos, HS, Brian Seo, BA, Christopher Sison, BS, Silvia Perez, BS, Stephanie Chao, HS, Kelly Miyasato, MPH, Julia Higgins, MS, Zoila Luna, MHA, Anita Menchaca, BS, Norma Gonzalez, MA, Vicky Robledo, BS, Karen Carig, BS, Kirstie Baker, HS, David Ellenbogen, BS, Daniel Bluemel, AA, Theo Sanford, BS, Daisy Linares, HS, Mei Tran, BA, Lorane Nava, HS, Michelle Oberoi, BS, Mark Romero, HS, Vivian Chiguil, HS, Grantley Bynum-Bain, BA, Monica Kim, BS, Carolina Mendiguren, MEM, Xiwen Huang, MPH, Monika Smith, HS.
Meeting Presentation: This study was presented at the annual meeting of the Association for Research in Vision and Ophthalmology; May 3, 2015; Denver, Colorado.
Additional Contributions: Melissa Kasilian, BA, assisted with editing the figures in this article and did not receive compensation for her work.
M. Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options. Br J Ophthalmol
. 2017;101(1):25-30.PubMedGoogle ScholarCrossref
et al. A photoreceptor cell-specific ATP-binding transporter gene (ABCR
) is mutated in recessive Stargardt macular dystrophy. Nat Genet
. 1997;15(3):236-246.PubMedGoogle ScholarCrossref
et al; Progression of Stargardt Disease Study Group. The natural history of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) studies: design and baseline characteristics: ProgStar report No. 1. Ophthalmology
. 2016;123(4):817-828.PubMedGoogle ScholarCrossref
et al. Emerging therapies for inherited retinal degeneration. Sci Transl Med
. 2016;8(368):368rv6.PubMedGoogle ScholarCrossref
III. Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Invest Ophthalmol Vis Sci
. 2008;49(2):479-489.PubMedGoogle ScholarCrossref
SW. Fundus autofluorescence imaging in age-related macular degeneration and geographic atrophy. Adv Exp Med Biol
. 2010;664:395-402.PubMedGoogle Scholar
et al. A longitudinal study of Stargardt disease: quantitative assessment of fundus autofluorescence, progression, and genotype correlations. Invest Ophthalmol Vis Sci
. 2013;54(13):8181-8190.PubMedGoogle ScholarCrossref
et al. Comparison of manual and semiautomated fundus autofluorescence analysis of macular atrophy in Stargardt disease phenotype. Retina
. 2016;36(6):1216-1221.PubMedGoogle ScholarCrossref
et al. Comparison of short-wavelength reduced-illuminance and conventional autofluorescence imaging in Stargardt macular dystrophy. Am J Ophthalmol
. 2016;168:269-278.PubMedGoogle ScholarCrossref
et al. Semiautomated image processing method for identification and quantification of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci
. 2011;52(10):7640-7646.PubMedGoogle ScholarCrossref
et al. the ProgStar Research Group. Quantitative characteristics of spectral-domain optical coherence tomography (SDOCT) in corresponding areas of decreased autofluorescence in patients with Stargardt disease. Poster presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology; May 3-7, 2015; Denver, Colorado. Poster 5924-A0095.
et al. Natural history of geographic atrophy progression secondary to age-related macular degeneration (Geographic Atrophy Progression Study). Ophthalmology
. 2016;123(2):361-368.PubMedGoogle ScholarCrossref
et al. Morpho-functional correlation of fundus autofluorescence in Stargardt disease. Br J Ophthalmol
. 2015;99(10):1354-1359.PubMedGoogle ScholarCrossref
S. Analysis of autofluorescent retinal images and measurement of atrophic lesion growth in Stargardt disease. Exp Eye Res
. 2010;91(2):143-152.PubMedGoogle ScholarCrossref
N. Progression of retinal pigment epithelial atrophy in Stargardt disease. Am J Ophthalmol
. 2012;154(1):146-154.PubMedGoogle ScholarCrossref
et al. Clinical and molecular characteristics of childhood-onset Stargardt disease. Ophthalmology
. 2015;122(2):326-334.PubMedGoogle ScholarCrossref
S, van Huet
et al. Early-onset stargardt disease: phenotypic and genotypic characteristics. Ophthalmology
. 2015;122(2):335-344.PubMedGoogle ScholarCrossref
LH, den Hollander
CB. Clinical and genetic characteristics of late-onset Stargardt’s disease. Ophthalmology
. 2012;119(6):1199-1210.PubMedGoogle ScholarCrossref
et al. Assessment of estimated retinal atrophy progression in Stargardt macular dystrophy using spectral-domain optical coherence tomography. Br J Ophthalmol
. 2016;100(7):956-962. PubMedGoogle ScholarCrossref
et al. Macular function in macular degenerations: repeatability of microperimetry as a potential outcome measure for ABCA4-associated retinopathy trials. Invest Ophthalmol Vis Sci
. 2012;53(2):841-852.PubMedGoogle ScholarCrossref